Cargando…

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer

Preclinical studies have shown synergistic effects when combining PARP1/2 inhibitors and platinum drugs in BRCA1/2 mutated cancer cell models. After a formulation change of olaparib from capsules to tablets, we initiated a dose finding study of olaparib tablets bidaily (BID) continuously with carbop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geenen, Jill J. J., Dackus, Gwen M. H. E., Schouten, Philip C., Pluim, Dick, Marchetti, Serena, Sonke, Gabe S., Jóźwiak, Katarzyna, Huitema, Alwin D. R., Beijnen, Jos H., Schellens, Jan H. M., Linn, Sabine C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Cancer Therapy and Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248128/ https://www.ncbi.nlm.nih.gov/pubmed/33539540 http://dx.doi.org/10.1002/ijc.33498

Ejemplares similares

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial
por: Schouten, Philip C., et al.
Publicado: (2016)

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
por: van der Noll, Ruud, et al.
Publicado: (2015)

Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
por: Gao, Qinglei, et al.
Publicado: (2022)

A real or apparent decrease in glomerular filtration rate in patients using olaparib?
por: Bruin, M. A. C., et al.
Publicado: (2020)

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
por: Lee, Jung-Min, et al.
Publicado: (2017)

Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer
por: Nakamura, Kohei, et al.
Publicado: (2020)

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
por: Keizer, Ron J., et al.
Publicado: (2011)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Olaparib: Transcending mutational barriers
por: Chandna, Abhishek
Publicado: (2019)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
por: Batalini, Felipe, et al.
Publicado: (2022)

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
por: de Haan, R., et al.
Publicado: (2019)

Defective DNA repair mechanisms in prostate cancer: impact of olaparib
por: De Felice, Francesca, et al.
Publicado: (2017)

Discontinuation of anti‐PD‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice
por: van Zeijl, Michiel C. T., et al.
Publicado: (2021)

Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report
por: Cheng, Yuan, et al.
Publicado: (2018)

The combination of olaparib and camptothecin for effective radiosensitization
por: Miura, Katsutoshi, et al.
Publicado: (2012)

Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells
por: Novohradsky, Vojtech, et al.
Publicado: (2018)

Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells
por: Zhao, Hui, et al.
Publicado: (2018)

The effect of trastuzumab on cardiac function in patients with HER2‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction
por: Bouwer, Nathalie I., et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Correction: Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells
por: Novohradsky, Vojtech, et al.
Publicado: (2018)

Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors
por: Herath, Nirmitha I., et al.
Publicado: (2019)

Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
por: Dackus, Gwen M. H. E., et al.
Publicado: (2020)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

Profile of olaparib in the treatment of advanced ovarian cancer
por: Chase, Dana M, et al.
Publicado: (2016)

Olaparib-Induced Immune-Mediated Liver Injury
por: Alshelleh, Mohammad, et al.
Publicado: (2022)

A case of hand-foot syndrome with olaparib
por: da Costa, Rafael Everton Assunção Ribeiro, et al.
Publicado: (2022)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
por: Mahdi, Haider, et al.
Publicado: (2021)

An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer
por: Prete, Alessandra Anna, et al.
Publicado: (2022)

Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy
por: Wang, Xue, et al.
Publicado: (2022)

Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
por: Fedier, André, et al.
Publicado: (2022)

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
por: Matsubara, Nobuaki, et al.
Publicado: (2023)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
por: Mansouri, Anita, et al.
Publicado: (2021)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study
por: Tannir, Nizar M., et al.
Publicado: (2021)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dnuefo322bjvm02m1f0rrelmvp